Abstract: A system is provided comprising an FTIR spectrometer configured to obtain a Fourier Transformed infrared (FTIR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample of the subject; a data processor operable with the FTIR spectrometer, and configured to analyze the infrared (IR) spectrum of the Peripheral Blood Mononuclear Cells (PBMC) sample of the subject by assessing a characteristic of the sample of the subject at at least one wavenumber; and an output unit, configured to generate an output indicative of the presence of a solid tumor, based on the infrared (IR) spectrum. Other embodiments are also provided.

Abstract: A system is provided comprising an FTIR spectrometer configured to obtain a Fourier Transformed infrared (FTIR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample of the subject; a data processor operable with the FTIR spectrometer, and configured to analyze the infrared (IR) spectrum of the Peripheral Blood Mononuclear Cells (PBMC) sample of the subject by assessing a characteristic of the sample of the subject at at least one wavenumber; and an output unit, configured to generate an output indicative of the presence of a solid tumor, based on the infrared (IR) spectrum. Other embodiments are also provided.

Abstract: A method including identifying a subject as possibly having a benign tumor in ovarian tissue and obtaining an infrared spectrum of a PBMC sample of the subject and assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 754.0±4 cm-1, 1103.6±4 cm-1, 1121.4±4 cm-1, 1346.1±4 cm-1, 1376.9±4 cm-1, 753.50±4 cm-1, 850.5±4 cm-1, 918.9±4 cm-1, 1058.7±4 cm-1, 1187.9±4 cm-1 and 1651.7±4 cm-1. Using a processor comparing, at the at least one wavenumber, the infrared spectrum to an infrared spectrum obtained from a PBMC sample from a person without a benign tumor, to detect a difference between the infrared spectrum of the PBMC sample of the subject and the infrared spectrum obtained from the PBMC sample from the person without a benign tumor. Other applications are also described.

Abstract: A method is provided including obtaining an infrared (IR) spectrum of a blood plasma sample by analyzing the blood plasma sample by infrared spectroscopy, and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other applications are also described.

Abstract: A system is provided comprising an FTIR spectrometer configured to obtain a Fourier Transformed infrared (FTIR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample of the subject; a data processor operable with the FTIR spectrometer, and configured to analyze the infrared (IR) spectrum of the Peripheral Blood Mononuclear Cells (PBMC) sample of the subject by assessing a characteristic of the sample of the subject at at least one wavenumber; and an output unit, configured to generate an output indicative of the presence of a solid tumor, based on the infrared (IR) spectrum. Other embodiments are also provided.

Abstract: A method is provided including obtaining an infrared (IR) spectrum of a blood plasma sample by analyzing the blood plasma sample by infrared spectroscopy, and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other applications are also described.

Abstract: A method is provided including obtaining an infrared (IR) spectrum of a blood plasma sample by analyzing the blood plasma sample by infrared spectroscopy, and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other applications are also described.

Abstract: A method is provided including obtaining an infrared (IR) spectrum of a blood plasma sample by analyzing the blood plasma sample by infrared spectroscopy, and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other applications are also described.

Abstract: A method including identifying a subject as possibly having a benign tumor in ovarian tissue and obtaining an infrared spectrum of a PBMC sample of the subject and assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 754.0±4 cm-1, 1103.6±4 cm-1, 1121.4±4 cm-1, 1346.1±4 cm-1, 1376.9±4 cm-1, 753.50±4 cm-1, 850.5±4 cm-1, 918.9±4 cm-1, 1058.7±4 cm-1, 1187.9±4 cm-1 and 1651.7±4 cm-1. Using a processor comparing, at the at least one wavenumber, the infrared spectrum to an infrared spectrum obtained from a PBMC sample from a person without a benign tumor, to detect a difference between the infrared spectrum of the PBMC sample of the subject and the infrared spectrum obtained from the PBMC sample from the person without a benign tumor. Other applications are also described.

Abstract: A method is provided comprising, obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample of a subject by analyzing the sample by infrared spectroscopy; analyzing the infrared spectrum using a processor (22), and based on the analyzing using the processor, using an output device (24), generating an output indicative of the presence of a benign tumor of the subject. Other applications are also described.

Abstract: A method is provided including obtaining an infrared (IR) spectrum of a blood plasma sample by analyzing the blood plasma sample by infrared spectroscopy, and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other applications are also described.

Abstract: A method is provided including obtaining an infrared (IR) spectrum of a blood plasma sample by analyzing the blood plasma sample by infrared spectroscopy, and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other applications are also described.

Abstract: A method is provided comprising, obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample by infrared spectroscopy; and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other embodiments are also provided.

Abstract: A method is provided comprising, obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample by infrared spectroscopy; and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other embodiments are also provided.

Abstract: A method is provided comprising, obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample of a subject by analyzing the sample by infrared spectroscopy; analyzing the infrared spectrum using a processor (22), and based on the analyzing using the processor, using an output device (24), generating an output indicative of the presence of a benign tumor of the subject. Other applications are also described.

Abstract: A method is provided including obtaining an infrared (IR) spectrum of a blood plasma sample by analyzing the blood plasma sample by infrared spectroscopy, and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other applications are also described.

Abstract: A method is provided comprising, obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample by infrared spectroscopy; and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other embodiments are also provided.

Abstract: A method for diagnosis of a hematological malignancy of a subject is provided. The method comprises obtaining a second derivative of an infrared (IR) spectrum of a population of mononuclear cells by analyzing the population of mononuclear cells by infrared spectroscopy, and based on the second derivative of the infrared spectrum, generating an output indicative of the presence of a hematological malignancy. Other applications are also described.

Abstract: The invention presents methods of using Fourier transform infrared microspectroscopy (FTIR-MSP) for distinguishing between normal and abnormal human cells and for diagnosis and digital staging of human cells on biopsied samples. The invention further presents computational methods employing neural network (NN) based classifiers for diagnosis and digital staging of adenomatous polyp and malignant tissue types of biopsied samples of human cells.